GENSIGHT BIOLOGICS
GenSight Biologics develops gene therapy-based treatments for retinal degenerative diseases. GenSight Biologics is a privately owned biopharmaceutical company, dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases. Based on recent results obtained by the teams of its scientific founders, the company develops innovative approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from very low vision or blindness.
GENSIGHT BIOLOGICS
Industry:
Biotechnology Genetics Health Care Medical
Founded:
2012-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.gensight-biologics.com
Total Employee:
11+
Status:
Active
Contact:
+33 1 76 21 72 20
Email Addresses:
[email protected]
Total Funding:
188.93 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt WordPress Google Universal Analytics Apache Wordpress Plugins
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Kodiak Sciences
Kodiak is designing and developing novel therapies for the treatment of retinal disease.
ORIG3N
ORIG3N is a biotechnology company developing breakthrough treatments for rare genetically inherited diseases.
Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Invus
Invus investment in Post-IPO Equity - GenSight Biologics
Arix Bioscience
Arix Bioscience investment in Post-IPO Equity - GenSight Biologics
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Equity - GenSight Biologics
Kreos Capital
Kreos Capital investment in Post-IPO Debt - GenSight Biologics
3sbio
3sbio investment in Post-IPO Debt - GenSight Biologics
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Debt - GenSight Biologics
Sofinnova Partners
Sofinnova Partners investment in Post-IPO Equity - GenSight Biologics
Abingworth
Abingworth investment in Series B - GenSight Biologics
Versant Ventures
Versant Ventures investment in Series B - GenSight Biologics
Perceptive Advisors
Perceptive Advisors investment in Series B - GenSight Biologics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-01 | GenSight Biologics Appoints Sissel Rodahl as Senior Vice-President of Commercial Operations to Lead the Launch of LUMEVOQ® in Europe |
Official Site Inspections
http://www.gensight-biologics.com Semrush global rank: 3.41 M Semrush visits lastest month: 4.59 K
- Host name: coheractio-prod1.alwaysdata.net
- IP address: 185.31.40.193
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
